The Effect of Raloxifene on Markers of Bone Turnover in Older Women Living in Long-Term Care Facilities

Journal of the American Geriatrics Society

Volumn 52, Issue 5, 2004, Pages 779-783

  Hansdóttir, Helga ^a   Franzson, Leifur ^a   Prestwood, Karen ^b   Sigursson, Gunnar ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Elderly women; Long term care institutions; Markers of bone turnover; Osteoporosis; Raloxifene

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; OSTEOCALCIN; RALOXIFENE; VITAMIN D;

AGED; ANKLE EDEMA; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; NIGHT SWEAT; OSTEOPOROSIS; URINALYSIS; VITAMIN SUPPLEMENTATION;

ACID PHOSPHATASE; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE REMODELING; CALCIUM; COLLAGEN TYPE I; DATA INTERPRETATION, STATISTICAL; FEMALE; FRACTURES, BONE; HUMANS; LONG-TERM CARE; NURSING HOMES; OSTEOCALCIN; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; PHOSPHATES; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX FACTORS; TIME FACTORS; VITAMIN D;

EID: 2342527672     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2004.52218.x     Document Type: Article

References (23)

1. Cummings SR, Black DM, Rubin SM. Lifetime risk of hip, Colle's, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-2448.
2. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors. Lancet 1993;341:11-13.
3. Chandler JM, Zimmerman SI, Girman CJ et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 2000;284:972-977.
4. Silverman SL, Minshall ME, Shen W et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmeopausal women with osteoporosis. Arthritis Rheum 2001;44:2611-2619.
5. Ettinger B, Black S, Mitlak B et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
6. Villareal DT, Binder EF, Schechtman KB et al. Bone mineral density response to estrogen replacement in frail elderly women. JAMA 2001;286:815-820.
7. Melton LJ III, Koshla S, Atkinson EJ et al. Relationship of bone turnover to bone density and fractures. J Bone Min Res 1997;12:1083-1091.
8. Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: The Epidos Prospective Study. J Bone Min Res 1996;11:1531-1538.
9. Bjarnason NH, Sarkar S, Duong T et al. Six and twelve months changes in bone turnover are related to reduction on vertebral fracture risk during 3 years of taloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922-930.
10. Cristgau S, Rosenquist C, Alexendersen P et al. Clinical evaluation of the serum crosslaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptide. Clin Chem 1998;44:2290-2300.
11. Greenspan SL, Parker RA, Ferguson L et al. Early changes in biochemical markers of bone turnover predict the long term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Min Res 1998;13:1431-1438.
12. Ólafur Reykdal. Handbók um næringargildi matvæla. Rannsóknarstofnun Landbúnaoarins, 1998.
13. Greenspan SL, Schneider DL, McClung MR et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. Ann Intern Med 2002;136:742-746.
14. Prestwood KM, Gunness M, Muchmore DB et al. A comparison of the effect of raloxifene and estrogen on bone on postmenopausal women. J Clin Endocrinol Metab 2000;85:2097-2202.
15. Tsai KS, Yen ML, Pan HA et al. Raloxifene versus continuous combined estrogen/progestin therapy: Densitometry and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001;12: 1020-1025.
16. Johnell O, Scheele WH, Reginster JY et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87: 985-992.
17. Liberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Group. N Engl J Med 1995;333:1437-1443.
18. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
19. Prestwood KM, Pilbeam CC, Burleson JA et al. The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994;79:366-371.
20. Halleen JM, Alatalo SL, Suominen H et al. Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Min Res 2000;15:1337-1345.
21. Christianssen C, Riis BJ. 17 beta-estradiol and continuous norethisterone: A unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab 1990;71:836-841.
22. Pretwood KM, Panullo AM, Pilbeam CC et al. The effect of a short course of calcium and vitamin D on bone turnover in older women. Osteoporos Int 1996;6:314-319.
23. Riggs BL, O'Fallon WM, Muhs J et al. Lon-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover and bone loss in elderly women. J Bone Min Res 1998;13:168-174.